Pulmoner Hipertansiyonda Gelecek Perspektifleri
Özet
Pulmoner hipertansiyon, ilerleyici pulmoner vasküler yeniden şekillenme ve sağ ventrikül yetmezliği ile karakterize, yüksek morbidite ve mortaliteye sahip kompleks bir hastalık grubudur. Son yıllarda endotelin, nitrik oksit ve prostasiklin yolaklarını hedefleyen tedavilere rağmen hastalığın tamamen kontrol altına alınamaması, yeni terapötik hedeflerin araştırılmasına yol açmıştır. Bu bölümde pulmoner hipertansiyon alanındaki güncel gelişmeler ve geleceğe yönelik yaklaşımlar ele alınmıştır. Özellikle BMPR2/TGF-β sinyal yolunu hedefleyen sotatercept ile başlayan hastalık modifiye edici tedavi dönemi, pulmoner vasküler yeniden şekillenmenin biyolojik mekanizmalarına yönelik yeni bir yaklaşım sunmaktadır. Bunun yanı sıra tirozin kinaz inhibitörleri, serotonin sentez inhibitörleri, immünomodülatör tedaviler, metabolik ajanlar ile gen ve hücre tedavileri gelecek vadeden stratejiler arasında yer almaktadır. Kişiselleştirilmiş tedavi yaklaşımı kapsamında risk sınıflandırması, biyobelirteçler, genetik profilleme ve omik teknolojilerin önemi giderek artmaktadır. Ayrıca yapay zeka destekli analizler, derin fenotipleme yöntemleri ve dijital sağlık uygulamaları tanı, risk değerlendirmesi ve hasta takibinde yeni fırsatlar sunmaktadır. Klinik araştırmalarda ise adaptif çalışma tasarımları, gerçek yaşam verileri, omik teknolojiler ve biyobelirteç temelli yaklaşımlar ön plana çıkmaktadır. Tüm bu gelişmeler, pulmoner hipertansiyon yönetiminin semptom kontrolünden biyolojik mekanizmaların hedeflendiği, daha hassas ve kişiselleştirilmiş bir döneme doğru evrildiğini göstermektedir.
Pulmonary hypertension is a complex group of diseases with high morbidity and mortality, characterized by progressive pulmonary vascular remodeling and right ventricular failure. In recent years, the fact that the disease cannot be fully controlled despite therapies targeting the endothelin, nitric oxide, and prostacyclin pathways has led to the investigation of new therapeutic targets. This chapter addresses current developments and future-oriented approaches in the field of pulmonary hypertension. In particular, the era of disease-modifying therapy that began with sotatercept, which targets the BMPR2/TGF-β signaling pathway, offers a new approach directed at the biological mechanisms of pulmonary vascular remodeling. In addition, tyrosine kinase inhibitors, serotonin synthesis inhibitors, immunomodulatory therapies, metabolic agents, and gene and cell therapies are among the promising strategies for the future. Within the scope of personalized treatment approaches, the importance of risk stratification, biomarkers, genetic profiling, and omics technologies is steadily increasing. Furthermore, artificial intelligence-assisted analyses, deep phenotyping methods, and digital health applications offer new opportunities in diagnosis, risk assessment, and patient follow-up. In clinical research, adaptive trial designs, real-world data, omics technologies, and biomarker-based approaches are coming to the fore. All these developments indicate that the management of pulmonary hypertension is evolving from symptom control toward a more precise and personalized era targeting the underlying biological mechanisms.
Referanslar
Mocumbi A, Humbert M, Saxena A, Jing Z-C, Sliwa K, Thienemann F, et al. Pulmonary hypertension. Nature Reviews Disease Primers. 2024;10(1):1.
Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. Jama. 2022;327(14):1379-91.
Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. European Respiratory Journal. 2012;39(2):329-43.
Hoeper MM. Sotatercept in pulmonary arterial hypertension: revolution, risk and the road ahead. European Respiratory Journal. 2025;66(4):2501633.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. New England Journal of Medicine. 2021;384(13):1204-15.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. New England Journal of Medicine. 2023;388(16):1478-90.
Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept in patients with pulmonary arterial hypertension at high risk for death. New England Journal of Medicine. 2025;392(20):1987-2000.
McLaughlin VV, Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, et al. Sotatercept for pulmonary arterial hypertension within the first year after diagnosis. New England Journal of Medicine. 2025;393(16):1599-611.
Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y, et al., editors. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Seminars in respiratory and critical care medicine; 2013: Thieme Medical Publishers.
Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128-38.
Frantz RP, McLaughlin VV, Sahay S, Subías PE, Zolty RL, Benza RL, et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Respiratory Medicine. 2024;12(7):523-34.
Launay J-M, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature medicine. 2002;8(10):1129-35.
Sitbon O, Skride A, Feldman J, Sahay S, Shlobin OA, Mclaughlin V, et al. Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial. The Lancet Respiratory Medicine. 2024;12(11):865-76.
Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circulation research. 2009;104(2):236-44.
Hernández-Sánchez J, Harlow L, Church C, Gaine S, Knightbridge E, Bunclark K, et al. Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulmonary circulation. 2017;8(1):2045893217735820.
Xu W, Janocha AJ, Erzurum SC. Metabolism in pulmonary hypertension. Annual review of physiology. 2021;83(1):551-76.
Sitbon O, Boucly A, Weatherald J, Antigny F, Guignabert C, Jevnikar M, et al. Drugs targeting novel pathways in pulmonary arterial hypertension. European Respiratory Journal. 2025;66(2).
Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circulation research. 2015;117(7):645-54.
Chen X, Xu L, Shi H. Emerging biomaterials and bio-nano interfaces in pulmonary hypertension therapy: transformative strategies for personalized treatment. Frontiers in Bioengineering and Biotechnology. 2025;13:1567783.
Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65.
Rådegran G, Kjellström B, Ekmehag B, Larsen F, Rundqvist B, Blomquist SB, et al. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. Scandinavian cardiovascular journal. 2016;50(4):243-50.
Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164-72.
Galiè N, Barberà JA, Frost AE, Ghofrani H-A, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine. 2015;373(9):834-44.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. New England Journal of Medicine. 2015;373(26):2522-33.
Yanni M, Ali H, Soesanto AM, Darwin E. GDF-15, Galectin-3, and sST2 as Biomarkers for Right Ventricular Dysfunction in Patients with Pulmonary Arterial Hypertension: A Systematic Review. Journal of Applied Bioanalysis. 2025;11(3):674-83.
Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, et al. PVDOMICS: a multi-center study to improve understanding of pulmonary vascular disease through phenomics. Circulation research. 2017;121(10):1136-9.
Southgate L, Machado RD, Gräf S, Morrell NW. Molecular genetic framework underlying pulmonary arterial hypertension. Nature Reviews Cardiology. 2020;17(2):85-95.
Zhu N, Pauciulo MW, Welch CL, Lutz KA, Coleman AW, Gonzaga-Jauregui C, et al. Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. Genome Medicine. 2019;11(1):69.
Attaripour Esfahani S, Baba Ali N, Farina JM, Scalia IG, Pereyra M, Abbas MT, et al. A comprehensive review of artificial intelligence (AI) applications in pulmonary hypertension (PH). Medicina. 2025;61(1):85.
Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323-37.
Hughes AM, Lindsey A, Annis J, Burke K, Master H, Silverman‐Lloyd LG, et al. Physical activity, sleep, and quality of life in pulmonary arterial hypertension: novel insights from wearable devices. Pulmonary Circulation. 2025;15(2):e70069.
Savarese G, Paolillo S, Costanzo P, D'Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. Journal of the American College of Cardiology. 2012;60(13):1192-201.
